Journal Information
Vol. 15. Issue 4.
Pages 301-304 (July - August 2011)
Share
Share
Download PDF
More article options
Vol. 15. Issue 4.
Pages 301-304 (July - August 2011)
Original article
Open Access
Biofilm production using distinct media and antimicrobial susceptibility profile of Pseudomonas aeruginosa
Visits
2621
Leandro Reus Rodrigues Perez1,
Corresponding author
leandro.reus@gmail.com

Correspondence to: Laboratory of Clinical Analysis, Faculty of Pharmacy, UFRGS, Av. Ipiranga, 2752/303, 90610-000, Porto Alegre, RS Brazil Phone: +55 (51) 33085412 Fax: +55 (51) 33085437.
, Afonso Luís Barth2
1 Microbiology Unit, Hospital Mãe de Deus; Post-graduation Program in Pharmaceutical Sciences, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil
2 Post-graduation Program in Pharmaceutical Sciences, UFRGS; Microbiology Unit and Molecular Biology Service, Hospital de Clínicas, Porto Alegre, RS, Brazil
This item has received

Under a Creative Commons license
Article information
Abstract

Biofilm production is an important mechanism for bacterial survival and its occurrence together with antimicrobial resistance represents a challenge for clinical management. Here, we evaluated the ability for biofilm production among P. aeruginosa isolates from patients with or without cystic fibrosis (CF) using two distinct media, besides determining the antimicrobial susceptibility profile of these isolates for eight antimicrobial agents. The ability for biofilm production when TSB medium was used was higher than when used CF sputum media (p=0.0198). However, P. aeruginosa isolates from CF have demonstrated similar performance for biofilm production, independently of the medium used. Besides, among the biofilm-producing isolates, those recovered from CF were more resistant to the carbapenems (meropenem and imipenem) agents than those isolates from non-CF isolates.

Keywords:
biofilm
Pseudomonas aeruginosa
cystic fibrosis
antimicrobial resistance
Full text is only aviable in PDF
References
[1.]
J. Emerson, M. Rosenfeld, S. McNamara, B. Ramsey, R.L. Gibson.
Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.
Pediatr Pulmonol, 34 (2002), pp. 91-100
[2.]
M.R. Kosorok, L. Zeng, S.E. West, et al.
Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition.
Pediatr Pulmonol, 32 (2001), pp. 277-287
[3.]
D.D. Sriramulu, H. Lünsdorf, J.S. Lam, U. Römling.
Microcolony formation: a novel model of Pseudomonas aeruginosa for the cystic fibrosis lung.
J Med Microbiol, 54 (2005), pp. 667-676
[4.]
A.J. Jesaitis, M.J. Franklin, D. Berglund, et al.
Compromised host defense on Pseudomonas aeruginosa biofilms: characterization of neutrophil and biofilm interactions.
J Immunol, 171 (2003), pp. 4329-4339
[5.]
R. Singh, D. Paul, R.K. Jain.
Biofilms: implication in bioremediation.
Trends Microbiol, 14 (2006), pp. 389-397
[6.]
D. Worlitzsch, R. Tarran, M. Ulrich, et al.
Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients.
J Clin Invest, 109 (2002), pp. 317-325
[7.]
G.A. O’Toole, L.A. Pratt, P.I. Watnick, D.K. Newman, V.B. Weaver, R. Kolter.
Genetic approaches to study biofilms.
Methods Enzymol, 310 (1999), pp. 91-109
[8.]
S. Stepanovic, D. Vucovic, V. Hola, et al.
Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci.
[9.]
Clinical and Laboratory Standards Institute - CLSI. Performance standards for antimicrobial susceptibility testing. 19th informational supplement M100-S19. Wayne, PA: CLSI/(NCCLS), 2009.
[10.]
J.W. Costerton, P.S. Stewart, E.P. Greenberg.
Bacterial biofilms: a common cause of persistent infections.
Science, 284 (1999), pp. 1318-1322
[11.]
B. Frederiksen, S. Lanng, C. Koch, N. Hoiby.
Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment.
[12.]
F. Delissalde, C.F. Amábile-Cuevas.
Comparison of antibiotic susceptibility and plasmid content, between biofilm producing and non-producing clinical isolates of Pseudomonas aeruginosa.
Int J Antimicrob Agents, 24 (2004), pp. 405-408
Copyright © 2011. Elsevier Editora Ltda.. All rights reserved
The Brazilian Journal of Infectious Diseases
Article options
Tools